Comparative Pharmacology
Head-to-head clinical analysis: MICONAZOLE 3 COMBINATION PACK versus NILSTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICONAZOLE 3 COMBINATION PACK versus NILSTAT.
MICONAZOLE 3 COMBINATION PACK vs NILSTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Miconazole inhibits fungal cytochrome P450 14α-demethylase (CYP51), thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This leads to increased membrane permeability and fungal cell death.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity and cause leakage of intracellular contents, leading to fungal cell death.
Intravaginal: 1 applicatorful (100 mg) at bedtime for 3 consecutive nights.
Topical: Apply 100,000 units/g cream or ointment to affected area twice daily. Oral suspension: 100,000 units/mL; 4-6 mL swish and swallow four times daily for 14 days. Oral tablets: 500,000 units; 1-2 tablets three times daily.
None Documented
None Documented
Terminal elimination half-life is 20-25 hours (intravaginal administration). This long half-life supports a 3-day dosing regimen, maintaining therapeutic concentrations.
Not well-defined due to minimal systemic absorption following oral or topical administration; estimated to be <1 hour in systemic circulation if absorbed.
Renal: approximately 10-20% as unchanged drug; fecal: >50% as metabolites; biliary: minor route. The majority is eliminated via feces as metabolites, reflecting hepatic metabolism and biliary excretion.
Primarily via feces as unchanged drug; negligible urinary excretion (<1%).
Category A/B
Category C
Antifungal
Antifungal